A Novel Bromodomain and Extra-terminal Domain Inhibitors (BETi) that Reverses HIV-1 Latency by Liu, Shuai et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Research Retreat 
2017 UMass Center for Clinical and 
Translational Science Research Retreat 
May 16th, 1:45 PM 
A Novel Bromodomain and Extra-terminal Domain Inhibitors 
(BETi) that Reverses HIV-1 Latency 
Shuai Liu 
University of Massachusetts Boston 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat 
 Part of the Medicinal-Pharmaceutical Chemistry Commons, Translational Medical Research 
Commons, and the Virus Diseases Commons 
Liu S, Jean M, Zhang W, Zhu J. (2017). A Novel Bromodomain and Extra-terminal Domain Inhibitors (BETi) 
that Reverses HIV-1 Latency. UMass Center for Clinical and Translational Science Research Retreat. 
Retrieved from https://escholarship.umassmed.edu/cts_retreat/2017/posters/47 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
A NOVEL BROMODOMAIN AND EXTRA-TERMINAL DOMAIN INHIBITORS (BETI) THAT 
REVERSES HIV-1 LATENCY 
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1Department of Chemistry, University of Massachusetts Boston; 2Department of Microbiology 
and Immunology, University of Rochester Medical Center, Rochester, NY 
 
Although combinatory antiretroviral therapy (cART) is effective to reduce HIV-1 viremia, it does 
not eliminate HIV-1 infection. HIV-1 remains latent with the presence of cART, impeding the 
cure of AIDS. Recently, latency-reversing agents (LRAs) have been developed to purge latent 
HIV-1, providing an intriguing strategy for eradication of residual, latent viral reservoirs. Our 
earlier studies show that antagonism of HIV-1 competitive factor bromodomain containing 4 
(BRD4) using bromodomain and extra-terminal domain inhibitor (BETi) JQ1 may facilitate the 
reversal of HIV-1 latency. BETis have recently emerged as a class of compounds that are 
promising for both the anticancer and HIV-1 latency-reversing uses. However, the current BETis, 
including JQ1, are modest to reverse HIV-1 latency as a single drug, which complicates the 
study of the underlining mechanisms. BETis, which are more potent and easier for synthesis, 
are currently under active development. UMB-32 is a novel BETi based on an imidazo[1,2-
a]pyrazine scaffold. We screened 61 UMB-32 derivatives and identified that one BETi, UMB-136, 
reactivates HIV-1 in multiple cell models of HIV-1 latency with better efficiency than JQ1 and 
UMB-32. Furthermore, UMB-136 enhances the latency-reversing effect of PKC activators 
(Prostratin, Bryostatin) in CD8-depleted PBMCs containing HIV-1 latent reservoirs. Thus, our 
results illustrate that structurally improved BETis, such as UMB-136, could be use as promising 
LRAs for HIV-1 eradication. 
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